Barclays Maintains Overweight on Twist Bioscience, Raises Price Target to $45
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Luke Sergott has maintained an Overweight rating on Twist Bioscience (NASDAQ:TWST) and increased the price target from $30 to $45.
January 25, 2024 | 2:58 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Barclays analyst Luke Sergott maintains an Overweight rating on Twist Bioscience and raises the price target from $30 to $45.
The increase in price target by Barclays reflects a positive outlook on Twist Bioscience's future performance. This endorsement from a reputable analyst is likely to instill confidence in investors and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100